Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab

Open Access
Publisher Website
Google Scholar
Abstract
Sir, Inhibitors of tumour necrosis factor α (TNF‐α; monoclonal antibodies or soluble receptors) have proven their efficacy in the treatment of rheumatoid arthritis (RA) and are currently under investigation in other chronic inflammatory diseases. However, an increase in infectious complications is noticed with these molecules. We report an RA patient who developed haemophagocytic syndrome (HPS) while she was being treated with infliximab.

This publication has 0 references indexed in Scilit: